Co.don

Co.don EBIT Margin

Delisted

The EBIT Margin (Operating Margin) of Co.don (CNWK.DE) as of Nov 10, 2026 is -175.82 %. In the previous year, EBIT Margin (Operating Margin) was -137.79 % — a change of 27.60% (lower).

EBIT Margin

-175.82 %

YoY

27.60%

Last updated:

EBIT Margin (Operating Margin) of Co.don is 2020 -175.82 % . EBIT Margin (Operating Margin) of Co.don was 2019 -137.79 % . It decreases by 27.60% lower compared to the previous year.

For Co.don, the operating (EBIT) margin of -175.8% is down versus -65.2% a few years ago.

The Co.don EBIT Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT Margin
Date
EBIT Margin
Jan 1, 2013
-0.73 EUR
Jan 1, 2014
-55.67 EUR
Jan 1, 2015
-56.21 EUR
Jan 1, 2016
-65.16 EUR
Jan 1, 2017
-101.79 EUR
Jan 1, 2018
-151.41 EUR
Jan 1, 2019
-137.79 EUR
Jan 1, 2020
-175.82 EUR
The Co.don EBIT Margin history
YEAREBIT MarginYoY
-175.82 %+27.60%
-137.79 %-9.00%
-151.41 %+48.76%
-101.79 %+56.20%
-65.16 %+15.93%
-56.21 %+0.96%
-55.67 %+7,476.69%
-0.73 %-16.95%
-0.88 %+101.24%
-0.44 %-28.25%
-0.61 %-28.93%
-0.86 %+30.55%
-0.66 %-48.67%
-1.29 %-57.11%
-3.00 %-33.90%
-4.54 %+72.81%
-2.63 %-66.68%
-7.88 %+29.46%
-6.09 %+27.20%
-4.79 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Co.don Stock analysis

What does Co.don do? Co.don AG is a German company specializing in regenerative medicine. The company was founded in 1993 and is headquartered in Teltow near Berlin. Co.don aims to develop innovative therapies for tissue and joint damage to enable faster recovery for patients. Co.don's business model is based on the concept of tissue engineering. The company produces autologous cell therapies based on a patient's own cells. This means that the patient's own tissue is harvested to cultivate new and healthy cells that can be implanted back into the patient's body. Co.don offers various divisions to best meet the needs of patients. One of the most well-known divisions is cartilage cell therapy, which was developed to provide patients with the opportunity to heal damaged cartilage tissue in a gentle and effective manner. Another area in which the company operates is bone cell therapy. Autologous bone cells are produced to regenerate fractured or diseased bones. The company also has a division for skin-based cell therapy, which aims to heal tissue defects and minimize scarring. Co.don also offers various products tailored to the specific needs of patients. One of the most well-known products is the "Co.don Chondrosphere®" implant, made from autologous cartilage cell tissue. This implant is used to repair cartilage damage in joints and other areas of the body. Another product offered by the company is the "Co.don ViviSpray®" bone substitute material. It is produced by mixing autologous bone cells with a carrier material to promote natural bone formation. In recent years, the company has gained increasing international recognition and is now a well-known player in the field of regenerative medicine. The company has received numerous awards and has conducted several successful clinical trials that demonstrate the effectiveness of Co.don's products. Overall, Co.don AG is a company specializing in the production of autologous cell therapies. The company offers various divisions and manufactures products tailored to the specific needs of patients. With its innovative work, Co.don has contributed to revolutionizing the way tissue and joint damage are treated. Co.don is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Co.don stock

EBIT Margin (Operating Margin) of Co.don is -175.82 % in 2020.

EBIT Margin (Operating Margin) of Co.don changed from -137.79 % to -175.82 %, representing a 27.60% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBIT Margin (Operating Margin) Co.don since 2006 – with annual values, charts, and detailed analysis.

EBIT Margin measures operating profitability as a percentage of revenue. It shows how much profit a company makes from operations before interest and taxes.

A 'good' varies by industry and company stage. On Eulerpool, you can compare EBIT Margin (Operating Margin)'s Co.don with sector peers and the industry average to assess whether it is attractive.

To evaluate EBIT Margin (Operating Margin)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EBIT Margin (Operating Margin).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Margins — Co.don

Gross MarginEBIT MarginEBITDA MarginNet MarginFCF MarginR&D / RevenueTax RatePayout RatioPre-Tax MarginOCF MarginSGA/RevenueOpEx/RevenueReinvestment Rate

All Key Metrics — Co.don